Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

New York Presbyterian Hospital Weill Cornell Med Ctr, New York

Duke University Medical Center Duke University Medical Ctr, Durham

Emory University School of Medicine/Winship Cancer Institute Emory University Med School, Atlanta

MD Anderson Cancer Center - Orlando, Orlando

University of Tennessee Cancer Institute Univ Tennessee Cancer, Memphis

Indiana University Simon Cancer Center, Indianapolis

Karmanos Cancer Institute Karmanos-1, Detroit

Medical College of Wisconsin, Milwaukee

University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4, Madison

Mayo Clinic - Rochester Mayo Lymphoma Group, Rochester

Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer, Chicago

Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201, St Louis

University of California at Los Angeles UCLS School of Medicine, Los Angeles

Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village

Dana Farber Cancer Institute, Boston

University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston